Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in Active Ankylosing Spondylitis
NCT02963506Phase 2Completed
- Sponsor
- UCB
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of bimekizumab in ankylosing spondylitis (AS) (5 arms), sponsored by UCB. Primary endpoint: Assessment of SpondyloArthritis International Society 40% Response at 12 weeks. Started Oct 2016; status: completed.
02
Drugs
bimekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02963506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963506.